Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
NEW YORK, Dec. 27, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Cempra, Inc. securities (NASDAQ:CEMP) from May 1, 2016 through November 1, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Cempra investors under the federal securities laws.
To join the Cempra class action, go to http://www.rosenlegal.com/cases-985.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) one of Cempra’s lead product candidate, solithromycin, posed significant safety risks for hepatotoxicity; and (2) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-985.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
